Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Accured: 2024-2025

Historic Receivables - Accured for SAB Biotherapeutics (SABS) over the last 1 years, with Sep 2025 value amounting to $560,000.

  • SAB Biotherapeutics' Receivables - Accured rose 477.04% to $560,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $560,000, marking a year-over-year increase of 477.04%. This contributed to the annual value of $55,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Receivables - Accured is $560,000, which was up 2,518.54% from $21,386 recorded in Q1 2025.
  • In the past 5 years, SAB Biotherapeutics' Receivables - Accured registered a high of $560,000 during Q3 2025, and its lowest value of $21,386 during Q1 2025.
  • Over the past 2 years, SAB Biotherapeutics' median Receivables - Accured value was $145,140 (recorded in 2024), while the average stood at $191,944.
  • Over the last 5 years, SAB Biotherapeutics' Receivables - Accured had its largest YoY gain of 477.04% in 2025, and its largest YoY loss of 88.93% in 2025.
  • Over the past 2 years, SAB Biotherapeutics' Receivables - Accured (Quarterly) stood at $55,000 in 2024, then surged by 477.04% to $560,000 in 2025.
  • Its Receivables - Accured stands at $560,000 for Q3 2025, versus $21,386 for Q1 2025 and $55,000 for Q4 2024.